--- title: "AbbVie (ABBV) Q4 Earnings: What To Expect" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/274592031.md" description: "Pharmaceutical company AbbVie (ABBV) will report Q4 earnings this Wednesday. Last quarter, AbbVie exceeded revenue expectations by 1.2%, with revenues of $15.78 billion, a 9.1% year-on-year increase. Analysts expect a 7.6% revenue growth this quarter to $16.25 billion, with adjusted earnings of $2.65 per share. AbbVie has consistently beaten revenue estimates over the past two years. The stock price is currently $225.56, with an average analyst target of $243.35." datetime: "2026-02-03T03:17:51.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/274592031.md) - [en](https://longbridge.com/en/news/274592031.md) - [zh-HK](https://longbridge.com/zh-HK/news/274592031.md) --- > 支持的语言: [English](https://longbridge.com/en/news/274592031.md) | [繁體中文](https://longbridge.com/zh-HK/news/274592031.md) # AbbVie (ABBV) Q4 Earnings: What To Expect Pharmaceutical company AbbVie will be reporting earnings this Wednesday before market open. Here’s what to expect. AbbVie beat analysts’ revenue expectations by 1.2% last quarter, reporting revenues of $15.78 billion, up 9.1% year on year. It was a mixed quarter for the company, with a narrow beat of analysts’ constant currency revenue estimates but a miss of analysts’ full-year EPS guidance estimates. Is AbbVie a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members. This quarter, analysts are expecting AbbVie’s revenue to grow 7.6% year on year to $16.25 billion, improving from the 5.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.65 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. AbbVie has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 2.3% on average. Looking at AbbVie’s peers in the biotechnology segment, only Regeneron has reported results so far. It beat analysts’ revenue estimates by 2.7%, delivering year-on-year sales growth of 2.5%. The stock price was unchanged following the results. Read our full analysis of Regeneron’s earnings results here. Investors in the biotechnology segment have had steady hands going into earnings, with share prices flat over the last month. AbbVie is up 2.7% during the same time and is heading into earnings with an average analyst price target of $243.35 (compared to the current share price of $225.56). ### 相关股票 - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md) - [Abbvie (ABBV.US)](https://longbridge.com/zh-CN/quote/ABBV.US.md) - [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md) ## 相关资讯与研究 - [What You Need to Know Ahead of AbbVie’s Earnings Release](https://longbridge.com/zh-CN/news/281471479.md) - [AbbVie Leans Into Consumer Aesthetics With CoolMonth And Neurotoxin Pipeline](https://longbridge.com/zh-CN/news/281226447.md) - [AbbVie Dermatology Data Highlights Immunology Depth And Emerging Skin Disease Opportunities](https://longbridge.com/zh-CN/news/280880145.md) - [Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting® | ABBV Stock News](https://longbridge.com/zh-CN/news/281183064.md) - [Abingdon Health Wins £4.8m U.S. Contracts for Multiplex Lateral Flow Systems](https://longbridge.com/zh-CN/news/280966624.md)